Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -61.54%. A quarter ago, it was expected that this company would post a loss of $0.12 per share when it actually produced a loss of $0.15, delivering a surprise of -25%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. YmAbs Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $22.8 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 1.27%. This compares to year-ago revenues of $20.75 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings ...